MDSCs in cancer: Conceiving new prognostic and therapeutic targets

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1865, Issue 1, 2016, Pages 35-48

  De Sanctis, Francesco ^a   Solito, Samantha ^b   Ugel, Stefano ^a   Molon, Barbara ^c   Bronte, Vincenzo ^a   Marigo, Ilaria ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Cancer microenvironment; MDSC targeting approach; Myeloid derived suppressor cells

Indexed keywords

BIOLOGICAL MARKER; CCAAT ENHANCER BINDING PROTEIN BETA; CYCLOOXYGENASE 2; MICRORNA; STAT PROTEIN; TOLL LIKE RECEPTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL MATURATION; CLINICAL EFFECTIVENESS; HUMAN; IMMUNOREGULATION; INTRACELLULAR SIGNALING; MYELOID DERIVED SUPPRESSOR CELL; NEOPLASM; NONHUMAN; ONTOGENY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SUPPRESSOR CELL; TARGET CELL; TUMOR GROWTH; TUMOR PROMOTION; TUMOR VASCULARIZATION; ANIMAL; BONE MARROW CELL; DISEASE COURSE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; DISEASE PROGRESSION; HUMANS; IMMUNE TOLERANCE; MYELOID CELLS; NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84958765112     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.08.001     Document Type: Article

References (189)

1. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoue F., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
2. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
3. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
4. Delano M.J., Scumpia P.O., Weinstein J.S., Coco D., Nagaraj S., Kelly-Scumpia K.M., O'Malley K.A., Wynn J.L., Antonenko S., Al-Quran S.Z., Swan R., Chung C.S., Atkinson M.A., Ramphal R., Gabrilovich D.I., Reeves W.H., Ayala A., Phillips J., Laface D., Heyworth P.G., Clare-Salzler M., Moldawer L.L. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 2007, 204:1463-1474.
5. Skabytska Y., Wolbing F., Gunther C., Koberle M., Kaesler S., Chen K.M., Guenova E., Demircioglu D., Kempf W.E., Volz T., Rammensee H.G., Schaller M., Rocken M., Gotz F., Biedermann T. Cutaneous innate immune sensing of Toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity 2014, 41:762-775.
6. Norris B.A., Uebelhoer L.S., Nakaya H.I., Price A.A., Grakoui A., Pulendran B. Chronic but not acute virus infection induces sustained expansion of myeloid suppressor cell numbers that inhibit viral-specific T cell immunity. Immunity 2013, 38:309-321.
7. Van Ginderachter J.A., Beschin A., De Baetselier P., Raes G. Myeloid-derived suppressor cells in parasitic infections. Eur. J. Immunol. 2010, 40:2976-2985.
8. Crook K.R., Jin M., Weeks M.F., Rampersad R.R., Baldi R.M., Glekas A.S., Shen Y., Esserman D.A., Little P., Schwartz T.A., Liu P. Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease. J. Leukoc. Biol. 2015, 97(3):573-582.
9. Verschoor C.P., Johnstone J., Millar J., Dorrington M.G., Habibagahi M., Lelic A., Loeb M., Bramson J.L., Bowdish D.M. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J. Leukoc. Biol. 2013, 93:633-637.
10. Hoechst B., Ormandy L.A., Ballmaier M., Lehner F., Kruger C., Manns M.P., Greten T.F., Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008, 135:234-243.
11. Ko J.S., Zea A.H., Rini B.I., Ireland J.L., Elson P., Cohen P., Golshayan A., Rayman P.A., Wood L., Garcia J., Dreicer R., Bukowski R., Finke J.H. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 2009, 15:2148-2157.
12. Srivastava M.K., Bosch J.J., Thompson J.A., Ksander B.R., Edelman M.J., Ostrand-Rosenberg S. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol. Immunother. 2008, 57:1493-1504.
13. Mandruzzato S., Solito S., Falisi E., Francescato S., Chiarion-Sileni V., Mocellin S., Zanon A., Rossi C.R., Nitti D., Bronte V., Zanovello P. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 2009, 182:6562-6568.
14. Damuzzo V., Pinton L., Desantis G., Solito S., Marigo I., Bronte V., Mandruzzato S. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin. Cytom. 2015, 88:77-91.
15. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
16. Greten T.F., Manns M.P., Korangy F. Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol. 2011, 11:802-807.
17. Filipazzi P., Huber V., Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 2012, 61:255-263.
18. Marvel D., Gabrilovich D.I. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 2015, 1-9.
19. Talmadge J.E., Gabrilovich D.I. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 2013, 13:739-752.
20. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
21. Solito S., Marigo I., Pinton L., Damuzzo V., Mandruzzato S., Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann. N. Y. Acad. Sci. 2014, 1319:47-65.
22. Bennett J.A., Rao V.S., Mitchell M.S. Systemic bacillus Calmette-Guerin (BCG) activates natural suppressor cells. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:5142-5144.
23. Bronte V., Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat. Rev. Immunol. 2005, 5:641-654.
24. Gabrilovich D.I., Bronte V., Chen S.H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007, 67:425. (author reply 426).
25. Watson G.A., Fu Y.X., Lopez D.M. Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms. J. Leukoc. Biol. 1991, 49:126-138.
26. Seung L.P., Rowley D.A., Dubey P., Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:6254-6258.
27. Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16:53-65.
28. Bronte V., Chappell D.B., Apolloni E., Cabrelle A., Wang M., Hwu P., Restifo N.P. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 1999, 162:5728-5737.
29. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P., Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000, 96:3838-3846.
30. Dolcetti L., Peranzoni E., Ugel S., Marigo I., Fernandez Gomez A., Mesa C., Geilich M., Winkels G., Traggiai E., Casati A., Grassi F., Bronte V. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 2010, 40:22-35.
31. Movahedi K., Guilliams M., Van den Bossche J., Van den Bergh R., Gysemans C., Beschin A., De Baetselier P., Van Ginderachter J.A. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111:4233-4244.
32. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008, 181:5791-5802.
33. Noman M.Z., Desantis G., Janji B., Hasmim M., Karray S., Dessen P., Bronte V., Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 2014, 211:781-790.
34. Haverkamp J.M., Smith A.M., Weinlich R., Dillon C.P., Qualls J.E., Neale G., Koss B., Kim Y., Bronte V., Herold M.J., Green D.R., Opferman J.T., Murray P.J. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity 2014, 41:947-959.
35. Youn J.I., Collazo M., Shalova I.N., Biswas S.K., Gabrilovich D.I. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 2012, 91:167-181.
36. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 2010, 22:238-244.
37. Youn J.I., Kumar V., Collazo M., Nefedova Y., Condamine T., Cheng P., Villagra A., Antonia S., McCaffrey J.C., Fishman M., Sarnaik A., Horna P., Sotomayor E., Gabrilovich D.I. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat. Immunol. 2013, 14:211-220.
38. Shi Y., Ou L., Han S., Li M., Pena M.M., Pena E.A., Liu C., Nagarkatti M., Fan D., Ai W. Deficiency of Kruppel-like factor KLF4 in myeloid-derived suppressor cells inhibits tumor pulmonary metastasis in mice accompanied by decreased fibrocytes. Oncogenesis 2014, 3:e129.
39. Park Y.J., Song B., Kim Y.S., Kim E.K., Lee J.M., Lee G.E., Kim J.O., Kim Y.J., Chang W.S., Kang C.Y. Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells. Cancer Res. 2013, 73:5669-5681.
40. Auffray C., Sieweke M.H., Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 2009, 27:669-692.
41. Corzo C.A., Cotter M.J., Cheng P., Cheng F., Kusmartsev S., Sotomayor E., Padhya T., McCaffrey T.V., McCaffrey J.C., Gabrilovich D.I. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 2009, 182:5693-5701.
42. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., Castelli C., Mariani L., Parmiani G., Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 2007, 25:2546-2553.
43. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., Staehler M., Brugger W., Dietrich P.Y., Mendrzyk R., Hilf N., Schoor O., Fritsche J., Mahr A., Maurer D., Vass V., Trautwein C., Lewandrowski P., Flohr C., Pohla H., Stanczak J.J., Bronte V., Mandruzzato S., Biedermann T., Pawelec G., Derhovanessian E., Yamagishi H., Miki T., Hongo F., Takaha N., Hirakawa K., Tanaka H., Stevanovic S., Frisch J., Mayer-Mokler A., Kirner A., Rammensee H.G., Reinhardt C., Singh-Jasuja H. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 2012, 18:1254-1261.
44. Arihara F., Mizukoshi E., Kitahara M., Takata Y., Arai K., Yamashita T., Nakamoto Y., Kaneko S. Increase in CD14+ HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol. Immunother. 2013, 62:1421-1430.
45. Huang A., Zhang B., Wang B., Zhang F., Fan K.X., Guo Y.J. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol. Immunother. 2013, 62:1439-1451.
46. Lesokhin A.M., Hohl T.M., Kitano S., Cortez C., Hirschhorn-Cymerman D., Avogadri F., Rizzuto G.A., Lazarus J.J., Pamer E.G., Houghton A.N., Merghoub T., Wolchok J.D. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 2012, 72:876-886.
47. Jitschin R., Braun M., Buttner M., Dettmer-Wilde K., Bricks J., Berger J., Eckart M.J., Krause S.W., Oefner P.J., Le Blanc K., Mackensen A., Mougiakakos D. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 2014, 124:750-760.
48. Mougiakakos D., Jitschin R., von Bahr L., Poschke I., Gary R., Sundberg B., Gerbitz A., Ljungman P., Le Blanc K. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia 2013, 27:377-388.
49. Yu J., Du W., Yan F., Wang Y., Li H., Cao S., Yu W., Shen C., Liu J., Ren X. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 2013, 190:3783-3797.
50. Zoso A., Mazza E.M., Bicciato S., Mandruzzato S., Bronte V., Serafini P., Inverardi L. Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Eur. J. Immunol. 2014, 44:3307-3319.
51. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 2009, 58:49-59.
52. Gabitass R.F., Annels N.E., Stocken D.D., Pandha H.A., Middleton G.W. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 2011, 60:1419-1430.
53. Solito S., Falisi E., Diaz-Montero C.M., Doni A., Pinton L., Rosato A., Francescato S., Basso G., Zanovello P., Onicescu G., Garrett-Mayer E., Montero A.J., Bronte V., Mandruzzato S. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011, 118:2254-2265.
54. Zhang B., Wang Z., Wu L., Zhang M., Li W., Ding J., Zhu J., Wei H., Zhao K. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One 2013, 8:e57114.
55. Finke J., Ko J., Rini B., Rayman P., Ireland J., Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 2011, 11:856-861.
56. Kaufman H.L., Kim D.W., DeRaffele G., Mitcham J., Coffin R.S., Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 2010, 17:718-730.
57. OuYang L.Y., Wu X.J., Ye S.B., Zhang R.X., Li Z.L., Liao W., Pan Z.Z., Zheng L.M., Zhang X.S., Wang Z., Li Q., Ma G., Li J. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J. Transl. Med. 2015, 13:47.
58. Cui T.X., Kryczek I., Zhao L., Zhao E., Kuick R., Roh M.H., Vatan L., Szeliga W., Mao Y., Thomas D.G., Kotarski J., Tarkowski R., Wicha M., Cho K., Giordano T., Liu R., Zou W. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 2013, 39:611-621.
59. Condamine T., Gabrilovich D.I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011, 32:19-25.
60. Ries C.H., Cannarile M.A., Hoves S., Benz J., Wartha K., Runza V., Rey-Giraud F., Pradel L.P., Feuerhake F., Klaman I., Jones T., Jucknischke U., Scheiblich S., Kaluza K., Gorr I.H., Walz A., Abiraj K., Cassier P.A., Sica A., Gomez-Roca C., de Visser K.E., Italiano A., Le Tourneau C., Delord J.P., Levitsky H., Blay J.Y., Ruttinger D. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014, 25:846-859.
61. Zhu Y., Knolhoff B.L., Meyer M.A., Nywening T.M., West B.L., Luo J., Wang-Gillam A., Goedegebuure S.P., Linehan D.C., DeNardo D.G. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014, 74:5057-5069.
62. Priceman S.J., Sung J.L., Shaposhnik Z., Burton J.B., Torres-Collado A.X., Moughon D.L., Johnson M., Lusis A.J., Cohen D.A., Iruela-Arispe M.L., Wu L. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010, 115:1461-1471.
63. Kowanetz M., Wu X., Lee J., Tan M., Hagenbeek T., Qu X., Yu L., Ross J., Korsisaari N., Cao T., Bou-Reslan H., Kallop D., Weimer R., Ludlam M.J., Kaminker J.S., Modrusan Z., van Bruggen N., Peale F.V., Carano R., Meng Y.G., Ferrara N. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21248-21255.
64. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004, 64:6337-6343.
65. Marigo I., Bosio E., Solito S., Mesa C., Fernandez A., Dolcetti L., Ugel S., Sonda N., Bicciato S., Falisi E., Calabrese F., Basso G., Zanovello P., Cozzi E., Mandruzzato S., Bronte V. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010, 32:790-802.
66. Trikha M., Corringham R., Klein B., Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 2003, 9:4653-4665.
67. Gray M.J., Poljakovic M., Kepka-Lenhart D., Morris S.M. Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. Gene 2005, 353:98-106.
68. Gallina G., Dolcetti L., Serafini P., De Santo C., Marigo I., Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., Bicciato S., Bronte V. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 2006, 116:2777-2790.
69. Roth F., De La Fuente A.C., Vella J.L., Zoso A., Inverardi L., Serafini P. Aptamer-mediated blockade of IL4Ralpha triggers apoptosis of MDSCs and limits tumor progression. Cancer Res. 2012, 72:1373-1383.
70. Sade-Feldman M., Kanterman J., Ish-Shalom E., Elnekave M., Horwitz E., Baniyash M. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 2013, 38:541-554.
71. Sinha P., Okoro C., Foell D., Freeze H.H., Ostrand-Rosenberg S., Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 2008, 181:4666-4675.
72. Zhao X., Rong L., Li X., Liu X., Deng J., Wu H., Xu X., Erben U., Wu P., Syrbe U., Sieper J., Qin Z. TNF signaling drives myeloid-derived suppressor cell accumulation. J. Clin. Invest. 2012, 122:4094-4104.
73. Hu X., Li B., Li X., Zhao X., Wan L., Lin G., Yu M., Wang J., Jiang X., Feng W., Qin Z., Yin B., Li Z. Transmembrane TNF-alpha promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. J. Immunol. 2014, 192:1320-1331.
74. Katoh H., Wang D., Daikoku T., Sun H., Dey S.K., Dubois R.N. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013, 24:631-644.
75. Wu P., Wu D., Ni C., Ye J., Chen W., Hu G., Wang Z., Wang C., Zhang Z., Xia W., Chen Z., Wang K., Zhang T., Xu J., Han Y., Wu X., Wang J., Gong W., Zheng S., Qiu F., Yan J., Huang J. GammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 2014, 40:785-800.
76. Coffelt S.B., Kersten K., Doornebal C.W., Weiden J., Vrijland K., Hau C.S., Verstegen N.J., Ciampricotti M., Hawinkels L.J., Jonkers J., de Visser K.E. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 2015, 522:345-348.
77. Ma S., Cheng Q., Cai Y., Gong H., Wu Y., Yu X., Shi L., Wu D., Dong C., Liu H. IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res. 2014, 74:1969-1982.
78. Parker K.H., Sinha P., Horn L.A., Clements V.K., Yang H., Li J., Tracey K.J., Ostrand-Rosenberg S. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res. 2014, 74:5723-5733.
79. Sangaletti S., Tripodo C., Sandri S., Torselli I., Vitali C., Ratti C., Botti L., Burocchi A., Porcasi R., Tomirotti A., Colombo M.P., Chiodoni C. Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res. 2014, 74:4706-4719.
80. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mule J., Kerr W.G., Jove R., Pardoll D., Yu H. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11:1314-1321.
81. Kwak H.J., Liu P., Bajrami B., Xu Y., Park S.Y., Nombela-Arrieta C., Mondal S., Sun Y., Zhu H., Chai L., Silberstein L.E., Cheng T., Luo H.R. Myeloid cell-derived reactive oxygen species externally regulate the proliferation of myeloid progenitors in emergency granulopoiesis. Immunity 2015, 42:159-171.
82. Kusmartsev S., Gabrilovich D.I. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 2005, 174:4880-4891.
83. Schouppe E., Mommer C., Movahedi K., Laoui D., Morias Y., Gysemans C., Luyckx A., De Baetselier P., Van Ginderachter J.A. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur. J. Immunol. 2013, 43:2930-2942.
84. Xin H., Zhang C., Herrmann A., Du Y., Figlin R., Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009, 69:2506-2513.
85. Takaku S., Terabe M., Ambrosino E., Peng J., Lonning S., McPherson J.M., Berzofsky J.A. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int. J. Cancer. J. Int. Cancer 2010, 126:1666-1674.
86. Munera V., Popovic P.J., Bryk J., Pribis J., Caba D., Matta B.M., Zenati M., Ochoa J.B. Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin. Ann. Surg. 2010, 251:120-126.
87. Lesterhuis W.J., Punt C.J., Hato S.V., Eleveld-Trancikova D., Jansen B.J., Nierkens S., Schreibelt G., de Boer A., Van Herpen C.M., Kaanders J.H., van Krieken J.H., Adema G.J., Figdor C.G., de Vries I.J. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J. Clin. Invest. 2011, 121:3100-3108.
88. Manz M.G., Boettcher S. Emergency granulopoiesis. Nat. Rev. Immunol. 2014, 14:302-314.
89. Hirai H., Zhang P., Dayaram T., Hetherington C.J., Mizuno S., Imanishi J., Akashi K., Tenen D.G. C/EBPbeta is required for 'emergency' granulopoiesis. Nat. Immunol. 2006, 7:732-739.
90. van Dijk T.B., Baltus B., Raaijmakers J.A., Lammers J.W., Koenderman L., de Groot R.P. A composite C/EBP binding site is essential for the activity of the promoter of the IL-3/IL-5/granulocyte-macrophage colony-stimulating factor receptor beta c gene. J. Immunol. 1999, 163:2674-2680.
91. Zhang H., Nguyen-Jackson H., Panopoulos A.D., Li H.S., Murray P.J., Watowich S.S. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 2010, 116:2462-2471.
92. Thevenot P.T., Sierra R.A., Raber P.L., Al-Khami A.A., Trillo-Tinoco J., Zarreii P., Ochoa A.C., Cui Y., Del Valle L., Rodriguez P.C. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 2014, 41:389-401.
93. Hong E.H., Chang S.Y., Lee B.R., Kim Y.S., Lee J.M., Kang C.Y., Kweon M.N., Ko H.J. Blockade of Myd88 signaling induces antitumor effects by skewing the immunosuppressive function of myeloid-derived suppressor cells. Int. J. Cancer. J. Int. Cancer 2013, 132:2839-2848.
94. Pilon-Thomas S., Nelson N., Vohra N., Jerald M., Pendleton L., Szekeres K., Ghansah T. Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function. PLoS One 2011, 6:e27729.
95. Capietto A.H., Kim S., Sanford D.E., Linehan D.C., Hikida M., Kumosaki T., Novack D.V., Faccio R. Down-regulation of PLCgamma2-beta-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. J. Exp. Med. 2013, 210:2257-2271.
96. Li L., Zhang J., Diao W., Wang D., Wei Y., Zhang C.Y., Zen K. MicroRNA-155 and microRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J. Immunol. 2014, 192:1034-1043.
97. Sonda N., Simonato F., Peranzoni E., Cali B., Bortoluzzi S., Bisognin A., Wang E., Marincola F.M., Naldini L., Gentner B., Trautwein C., Sackett S.D., Zanovello P., Molon B., Bronte V. MiR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity 2013, 38:1236-1249.
98. Orabona C., Grohmann U. Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond. Methods Mol. Biol. 2011, 677:269-280.
99. Rodriguez P.C., Zea A.H., DeSalvo J., Culotta K.S., Zabaleta J., Quiceno D.G., Ochoa J.B., Ochoa A.C. l-Arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 2003, 171:1232-1239.
100. Srivastava M.K., Sinha P., Clements V.K., Rodriguez P., Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010, 70:68-77.
101. Mazzoni A., Bronte V., Visintin A., Spitzer J.H., Apolloni E., Serafini P., Zanovello P., Segal D.M. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 2002, 168:689-695.
102. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007, 87:245-313.
103. Andrew P.J., Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc. Res. 1999, 43:521-531.
104. Schmielau J., Nalesnik M.A., Finn O.J. Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin. Cancer Res. 2001, 7:933s-939s.
105. Otsuji M., Kimura Y., Aoe T., Okamoto Y., Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13119-13124.
106. Hardy L.L., Wick D.A., Webb J.R. Conversion of tyrosine to the inflammation-associated analog 3'-nitrotyrosine at either TCR- or MHC-contact positions can profoundly affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells. J. Immunol. 2008, 180:5956-5962.
107. Nagaraj S., Schrum A.G., Cho H.I., Celis E., Gabrilovich D.I. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 2010, 184:3106-3116.
108. Molon B., Ugel S., Del Pozzo F., Soldani C., Zilio S., Avella D., De Palma A., Mauri P., Monegal A., Rescigno M., Savino B., Colombo P., Jonjic N., Pecanic S., Lazzarato L., Fruttero R., Gasco A., Bronte V., Viola A. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 2011, 208:1949-1962.
109. De Sanctis F., Sandri S., Ferrarini G., Pagliarello I., Sartoris S., Ugel S., Marigo I., Molon B., Bronte V. The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment. Front. Immunol. 2014, 5:69.
110. Duraiswamy J., Freeman G.J., Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013, 73:6900-6912.
111. Loke P., Allison J.P. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:5336-5341.
112. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 2005, 23:515-548.
113. Savage N.D., de Boer T., Walburg K.V., Joosten S.A., van Meijgaarden K., Geluk A., Ottenhoff T.H. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J. Immunol. 2008, 181:2220-2226.
114. Serafini P., Mgebroff S., Noonan K., Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008, 68:5439-5449.
115. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
116. Sinha P., Clements V.K., Bunt S.K., Albelda S.M., Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 2007, 179:977-983.
117. Corzo C.A., Condamine T., Lu L., Cotter M.J., Youn J.I., Cheng P., Cho H.I., Celis E., Quiceno D.G., Padhya T., McCaffrey T.V., McCaffrey J.C., Gabrilovich D.I. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 2010, 207:2439-2453.
118. Doedens A.L., Stockmann C., Rubinstein M.P., Liao D., Zhang N., DeNardo D.G., Coussens L.M., Karin M., Goldrath A.W., Johnson R.S. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010, 70:7465-7475.
119. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L.M., Carbone D.P., Lin P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421.
120. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19:1423-1437.
121. Sceneay J., Chow M.T., Chen A., Halse H.M., Wong C.S., Andrews D.M., Sloan E.K., Parker B.S., Bowtell D.D., Smyth M.J., Moller A. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 2012, 72:3906-3911.
122. Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 2006, 8:1369-1375.
123. Oh K., Lee O.Y., Shon S.Y., Nam O., Ryu P.M., Seo M.W., Lee D.S. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013, 15:R79.
124. Zhu L., Li X., Chen Y., Fang J., Ge Z. High-mobility group box 1: a novel inducer of the epithelial-mesenchymal transition in colorectal carcinoma. Cancer Lett. 2015, 357:527-534.
125. Toh B., Wang X., Keeble J., Sim W.J., Khoo K., Wong W.C., Kato M., Prevost-Blondel A., Thiery J.P., Abastado J.P. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011, 9:e1001162.
126. Gao D., Joshi N., Choi H., Ryu S., Hahn M., Catena R., Sadik H., Argani P., Wagner P., Vahdat L.T., Port J.L., Stiles B., Sukumar S., Altorki N.K., Rafii S., Mittal V. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 2012, 72:1384-1394.
127. Li H., Collado M., Villasante A., Strati K., Ortega S., Canamero M., Blasco M.A., Serrano M. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009, 460:1136-1139.
128. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., Cordon-Cardo C., Pandolfi P.P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
129. Di Mitri D., Toso A., Chen J.J., Sarti M., Pinton S., Jost T.R., D'Antuono R., Montani E., Garcia-Escudero R., Guccini I., Da Silva-Alvarez S., Collado M., Eisenberger M., Zhang Z., Catapano C., Grassi F., Alimonti A. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature 2014, 515:134-137.
130. Panni R.Z., Sanford D.E., Belt B.A., Mitchem J.B., Worley L.A., Goetz B.D., Mukherjee P., Wang-Gillam A., Link D.C., Denardo D.G., Goedegebuure S.P., Linehan D.C. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunol. Immunother. 2014, 63:513-528.
131. Lu P., Yu B., Xu J. Cucurbitacin B regulates immature myeloid cell differentiation and enhances antitumor immunity in patients with lung cancer. Cancer Biother. Radiopharm. 2012, 27:495-503.
132. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., Dolcetti L., Bronte V., Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 2006, 203:2691-2702.
133. Califano J.A., Khan Z., Noonan K.A., Rudraraju L., Zhang Z., Wang H., Goodman S., Gourin C.G., Ha P.K., Fakhry C., Saunders J., Levine M., Tang M., Neuner G., Richmon J.D., Blanco R., Agrawal N., Koch W.M., Marur S., Weed D.T., Serafini P., Borrello I. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 2015, 21:30-38.
134. Noonan K.A., Ghosh N., Rudraraju L., Bui M., Borrello I. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunol. Res. 2014, 2:725-731.
135. Weed D.T., Vella J.L., Reis I.M., De la Fuente A.C., Gomez C., Sargi Z., Nazarian R., Califano J., Borrello I., Serafini P. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 2015, 21:39-48.
136. Sinha P., Parker K.H., Horn L., Ostrand-Rosenberg S. Tumor-induced myeloid-derived suppressor cell function is independent of IFN-gamma and IL-4Ralpha. Eur. J. Immunol. 2012, 42:2052-2059.
137. De Santo C., Serafini P., Marigo I., Dolcetti L., Bolla M., Del Soldato P., Melani C., Guiducci C., Colombo M.P., Iezzi M., Musiani P., Zanovello P., Bronte V. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4185-4190.
138. Thimmulappa R.K., Fuchs R.J., Malhotra D., Scollick C., Traore K., Bream J.H., Trush M.A., Liby K.T., Sporn M.B., Kensler T.W., Biswal S. Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxid. Redox Signal. 2007, 9:1963-1970.
139. Nagaraj S., Youn J.I., Weber H., Iclozan C., Lu L., Cotter M.J., Meyer C., Becerra C.R., Fishman M., Antonia S., Sporn M.B., Liby K.T., Rawal B., Lee J.H., Gabrilovich D.I. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin. Cancer Res. 2010, 16:1812-1823.
140. Wang Y.Y., Zhe H., Zhao R. Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment. Mol. Cancer 2014, 13:30.
141. Zha S., Yegnasubramanian V., Nelson W.G., Isaacs W.B., De Marzo A.M. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004, 215:1-20.
142. Serafini P. Editorial: PGE2-producing MDSC: a role in tumor progression?. J. Leukoc. Biol. 2010, 88:827-829.
143. Rodriguez P.C., Hernandez C.P., Quiceno D., Dubinett S.M., Zabaleta J., Ochoa J.B., Gilbert J., Ochoa A.C. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 2005, 202:931-939.
144. Veltman J.D., Lambers M.E., van Nimwegen M., Hendriks R.W., Hoogsteden H.C., Aerts J.G., Hegmans J.P. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 2010, 10:464.
145. Bracci L., Schiavoni G., Sistigu A., Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014, 21:15-25.
146. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., Albelda S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11:6713-6721.
147. Le H.K., Graham L., Cha E., Morales J.K., Manjili M.H., Bear H.D. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4 T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 2009, 9:900-909.
148. Tomihara K., Fuse H., Heshiki W., Takei R., Zhang B., Arai N., Nakamori K., Noguchi M. Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer. Oral Oncol. 2014, 50:457-467.
149. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., Martin F., Apetoh L., Rebe C., Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010, 70:3052-3061.
150. Chen J., Huang X., Huang G., Chen Y., Chen L., Song H. Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model. Cancer Biother. Radiopharm. 2012, 27:210-220.
151. Naiditch H., Shurin M.R., Shurin G.V. Targeting myeloid regulatory cells in cancer by chemotherapeutic agents. Immunol. Res. 2011, 50:276-285.
152. Kodumudi K.N., Woan K., Gilvary D.L., Sahakian E., Wei S., Djeu J.Y. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 2010, 16:4583-4594.
153. Tongu M., Harashima N., Monma H., Inao T., Yamada T., Kawauchi H., Harada M. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol. Immunother. 2013, 62:383-391.
154. Yanagimoto H., Mine T., Yamamoto K., Satoi S., Terakawa N., Takahashi K., Nakahara K., Honma S., Tanaka M., Mizoguchi J., Yamada A., Oka M., Kamiyama Y., Itoh K., Takai S. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci. 2007, 98:605-611.
155. Annels N.E., Shaw V.E., Gabitass R.F., Billingham L., Corrie P., Eatock M., Valle J., Smith D., Wadsley J., Cunningham D., Pandha H., Neoptolemos J.P., Middleton G. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol. Immunother. 2014, 63:175-183.
156. Montero A.J., Diaz-Montero C.M., Deutsch Y.E., Hurley J., Koniaris L.G., Rumboldt T., Yasir S., Jorda M., Garret-Mayer E., Avisar E., Slingerland J., Silva O., Welsh C., Schuhwerk K., Seo P., Pegram M.D., Gluck S. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res. Treat. 2012, 132:215-223.
157. Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 2008, 83:1032-1045.
158. Melani C., Sangaletti S., Barazzetta F.M., Werb Z., Colombo M.P. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007, 67:11438-11446.
159. Porembka M.R., Mitchem J.B., Belt B.A., Hsieh C.S., Lee H.M., Herndon J., Gillanders W.E., Linehan D.C., Goedegebuure P. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol. Immunother. 2012, 61:1373-1385.
160. Sanford D.E., Porembka M.R., Panni R.Z., Mitchem J.B., Belt B.A., Plambeck-Suess S.M., Lin G., Denardo D.G., Fields R.C., Hawkins W.G., Strasberg S.M., Lockhart A.C., Wang-Gillam A., Goedegebuure S.P., Linehan D.C. A study of zoledronic acid as neo-adjuvant, perioperative therapy in patients with resectable pancreatic ductal adenocarcinoma. J. Cancer Ther. 2013, 4:797-803.
161. Cheng P., Corzo C.A., Luetteke N., Yu B., Nagaraj S., Bui M.M., Ortiz M., Nacken W., Sorg C., Vogl T., Roth J., Gabrilovich D.I. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 2008, 205:2235-2249.
162. Xu J., Escamilla J., Mok S., David J., Priceman S., West B., Bollag G., McBride W., Wu L. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013, 73:2782-2794.
163. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., Boireau W., Rouleau A., Simon B., Lanneau D., De Thonel A., Multhoff G., Hamman A., Martin F., Chauffert B., Solary E., Zitvogel L., Garrido C., Ryffel B., Borg C., Apetoh L., Rebe C., Ghiringhelli F. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010, 120:457-471.
164. Zheng Y., Xu M., Li X., Jia J., Fan K., Lai G. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol. Immunol. 2013, 54:74-83.
165. Martin R.K., Saleem S.J., Folgosa L., Zellner H.B., Damle S.R., Nguyen G.K., Ryan J.J., Bear H.D., Irani A.M., Conrad D.H. Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. J. Leukoc. Biol. 2014, 96:151-159.
166. Terme M., Colussi O., Marcheteau E., Tanchot C., Tartour E., Taieb J. Modulation of immunity by antiangiogenic molecules in cancer. Clin. Dev. Immunol. 2012, 2012:492920.
167. Fricke I., Mirza N., Dupont J., Lockhart C., Jackson A., Lee J.H., Sosman J.A., Gabrilovich D.I. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 2007, 13:4840-4848.
168. Osada T., Chong G., Tansik R., Hong T., Spector N., Kumar R., Hurwitz H.I., Dev I., Nixon A.B., Lyerly H.K., Clay T., Morse M.A. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 2008, 57:1115-1124.
169. Rodriguez P.C., Ernstoff M.S., Hernandez C., Atkins M., Zabaleta J., Sierra R., Ochoa A.C. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009, 69:1553-1560.
170. Bruchard M., Mignot G., Derangere V., Chalmin F., Chevriaux A., Vegran F., Boireau W., Simon B., Ryffel B., Connat J.L., Kanellopoulos J., Martin F., Rebe C., Apetoh L., Ghiringhelli F. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 2013, 19:57-64.
171. Schilling B., Sucker A., Griewank K., Zhao F., Weide B., Gorgens A., Giebel B., Schadendorf D., Paschen A. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int. J. Cancer. J. Int. Cancer 2013, 133:1653-1663.
172. Najjar Y.G., Finke J.H. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front. Oncol. 2013, 3:49.
173. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003, 63:4441-4449.
174. Nefedova Y., Fishman M., Sherman S., Wang X., Beg A.A., Gabrilovich D.I. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007, 67:11021-11028.
175. Kusmartsev S., Su Z., Heiser A., Dannull J., Eruslanov E., Kubler H., Yancey D., Dahm P., Vieweg J. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 2008, 14:8270-8278.
176. Iclozan C., Antonia S., Chiappori A., Chen D.T., Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol. Immunother. 2013, 62:909-918.
177. Kulbersh J.S., Day T.A., Gillespie M.B., Young M.R. 1Alpha,25-dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells. Otolaryngol. Head Neck Surg. 2009, 140:235-240.
178. Walker D.D., Reeves T.D., de Costa A.M., Schuyler C., Young M.R. Immunological modulation by 1alpha,25-dihydroxyvitamin D3 in patients with squamous cell carcinoma of the head and neck. Cytokine 2012, 58:448-454.
179. Montero A.J., Diaz-Montero C.M., Kyriakopoulos C.E., Bronte V., Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J. Immunother. 2012, 35:107-115.
180. Meyer C., Cagnon L., Costa-Nunes C.M., Baumgaertner P., Montandon N., Leyvraz L., Michielin O., Romano E., Speiser D.E. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 2014, 63:247-257.
181. Tarhini A.A., Edington H., Butterfield L.H., Lin Y., Shuai Y., Tawbi H., Sander C., Yin Y., Holtzman M., Johnson J., Rao U.N., Kirkwood J.M. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014, 9:e87705.
182. Pico de Coana Y., Poschke I., Gentilcore G., Mao Y., Nystrom M., Hansson J., Masucci G.V., Kiessling R. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol. Res. 2013, 1:158-162.
183. Kitano S., Postow M.A., Ziegler C.G., Kuk D., Panageas K.S., Cortez C., Rasalan T., Adamow M., Yuan J., Wong P., Altan-Bonnet G., Wolchok J.D., Lesokhin A.M. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol. Res. 2014, 2:812-821.
184. Ortiz M.L., Kumar V., Martner A., Mony S., Donthireddy L., Condamine T., Seykora J., Knight S.C., Malietzis G., Lee G.H., Moorghen M., Lenox B., Luetteke N., Celis E., Gabrilovich D. Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells. J. Exp. Med. 2015, 212:351-367.
185. Qin H., Lerman B., Sakamaki I., Wei G., Cha S.C., Rao S.S., Qian J., Hailemichael Y., Nurieva R., Dwyer K.C., Roth J., Yi Q., Overwijk W.W., Kwak L.W. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat. Med. 2014, 20:676-681.
186. Kotsakis A., Harasymczuk M., Schilling B., Georgoulias V., Argiris A., Whiteside T.L. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J. Immunol. Methods 2012, 381:14-22.
187. Obermajer N., Muthuswamy R., Lesnock J., Edwards R.P., Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011, 118:5498-5505.
188. Mao Y., Poschke I., Wennerberg E., Pico de Coana Y., Egyhazi Brage S., Schultz I., Hansson J., Masucci G., Lundqvist A., Kiessling R. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res. 2013, 73:3877-3887.
189. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A.M., Frost T.J., Lush R.M., Antonia S., Gabrilovich D.I. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006, 66:9299-9307.